Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02034838|
Recruitment Status : Completed
First Posted : January 14, 2014
Last Update Posted : September 22, 2015
This is an open-label, single group study to determine the pharmacokinetic profile of atazanavir 300 mg daily boosted with ritonavir 100mg daily in HIV-infected patients over a period of 9 days.
Ritonavir and atazanavir are protease inhibitors used to treat HIV. However, ritonavir, when used at low doses (up to 100mg) does not have HIV activity, but will enhance (boost) the blood concentrations of other drugs like atazanavir.
Recently, a study showed that taking 50mg of ritonavir administered in an oral solution led to similar blood concentrations of atazanavir than when given with 100mg of ritonavir. Potential benefits associated with a lower dose of ritonavir may include a reduction of side effects such as upset stomach and an improvement in cholesterol level. This study will look at the amount of atazanavir into your blood when given with ritonavir in a tablet formulation at 50mg or 100mg with standard atazanavir dose (300mg).
|Condition or disease||Intervention/treatment||Phase|
|HIV Infection||Drug: atazanavir 300mg boosted with ritonavir 50 mg||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Microboosting of Atazanavir 300 mg With 50 mg Versus 100 mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study|
|Study Start Date :||January 2014|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||September 2015|
Experimental: atazanavir 300mg boosted with ritonavir 100mg
Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care.
Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive
Drug: atazanavir 300mg boosted with ritonavir 50 mg
atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.
atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)
- Pharmacokinetics [ Time Frame: 9 days ]main pharmacokinetic parameters of atazanavir: AUC0-24h, Cmax and Cmin.
- adverse events [ Time Frame: 9 days ]the main pharmacokinetic parameters of ritonavir: AUC0-24h, Cmax and Cmin, , adverse events and preference, as reported by patients during the study period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02034838
|The Ottawa Hospital|
|Ottawa, Ontario, Canada, K1H 8L6|
|Principal Investigator:||William Cameron, MD, FRCPC||The Ottawa Hospital|